The BiosearchTech Blog

New Product Line! ValuPanel™ Reagents

 Email Article |  Twitter |  Facebook |  digg it |   delicious |   StumbleUpon |   LinkedIn |   Technorati 

We are pleased to introduce ValuPanel Reagents, a new product line of mission-critical probe and primer sets that discriminate different strains of pathogens. This product line culminated from our successful collaboration with Centers for Disease Control and Prevention* (CDC) in response to the 2009 H1N1 pandemic. As of now, ValuPanel Reagents are available for both 2009 H1N1 and seasonal Influenza A subtyping.

*CDC does not endorse products or services.

The Details:
Probes are labeled with FAM and BHQ® dyes and all probes and primers are HPLC purified. ValuPanel Reagents are available with same day shipping via FedEx Priority for all orders placed before 2 PM (PST). ValuPanel Reagents are for Research Use Only (RUO) and currently resolve genetic signatures specific to the following viruses and subtypes:

2009 H1N1

• InfA for the universal detection of influenza A
• swInfA for the specific detection of swine influenza A
• swH1 for the specific detection of swine influenza H1
• RNase P for a positive control

Influenza A Subtyping

• InfA - for the universal detection of influenza A
• H1 subtype of influenza A
• H3 subtype of influenza A
• H5a subtype of influenza A
• H5b subtype of influenza A
• InfB - for the universal detection of influenza B
• RNase P for a positive control

Probe pricing for ValuPanel Reagents start from $135.00 and provide 5 nmol delivered. Forward and reverse primers are each available for $14.00 and provide 20 nmol delivered.

Learn more about Biosearch's NEW ValuPanel Reagents:

• 2009 H1N1 ValuPanel Reagents
• Influenza A Subtyping ValuPanel Reagents
  

BIOSEARCH TECHNOLOGIES TAKES LICENSE TO CDC H1N1 SIGNATURES AND INFLUENZA A SUB-TYPING PATENT

 Email Article |  Twitter |  Facebook |  digg it |   delicious |   StumbleUpon |   LinkedIn |   Technorati 

Biosearch Technologies announced today that the company has licensed from the CDC the novel H1N1 Influenza signatures along with the Influenza A sub-typing panel signatures.  This licensing agreement with the CDC makes Biosearch Technologies the first oligo manufacturer to have the right to manufacture and sell dual-labeled probes and primers bearing the H1N1 and Influenza A sub-typing signatures.

To read the entire story, read the full press release.